Corrigan C J, Haczku A, Gemou-Engesaeth V, Doi S, Kikuchi Y, Takatsu K, Durham S R, Kay A B
Department of Allergy and Clinical Immunology, National Heart and Lung Institute, London, United Kingdom.
Am Rev Respir Dis. 1993 Mar;147(3):540-7. doi: 10.1164/ajrccm/147.3.540.
Peripheral blood mononuclear cells (PBMC) and serum were obtained, on two occasions, from 15 asthmatic patients who required oral glucocorticoid therapy for moderate to severe disease exacerbations. Samples were obtained immediately before commencement of oral glucocorticoids (Day 1) and again after 7 days of treatment (Day 7), when lung function had significantly improved. Samples were also isolated on two occasions 7 days apart from a group of seven untreated volunteers. Expression of CD25, human lymphocyte antigen (HLA-)DR, CD45RA, and CD45RO on CD4 and CD8 T lymphocytes was measured by flow cytometry, and serum concentrations of interleukin-5 (IL-5) were measured using an enzyme-linked immunosorbent assay technique. On Day 1 the asthmatic patients showed significantly higher percentages, as compared with the control subjects of CD4 T lymphocytes expressing the markers CD25, HLA-DR, and CD45RO and significantly lower percentages of CD4 T cells expressing CD45RA. After glucocorticoid therapy, the percentages of CD4 T cells expressing CD25, HLA-DR, and CD45RO were significantly reduced in the asthmatic patients, and the percentages of those expressing CD45RA significantly increased so that by Day 7 expression of all four markers was no longer significantly different from that of the control subjects. By contrast, the percentages of CD8 T cells expressing HLA-DR, CD45RA, and CD45RO in the PBMC of the asthmatic patients on Day 1 were not significantly different from those in control subjects, whereas the percentages of CD25 expressing CD8 T cells were only marginally elevated. Glucocorticoid therapy resulted in no significant change in the expression of all four markers on CD T cells.(ABSTRACT TRUNCATED AT 250 WORDS)
在两个不同时间点，从15名因中重度疾病发作而需要口服糖皮质激素治疗的哮喘患者身上获取外周血单个核细胞（PBMC）和血清。样本在口服糖皮质激素治疗开始前即刻（第1天）采集，以及在治疗7天后（第7天）再次采集，此时肺功能已显著改善。还从一组7名未经治疗的志愿者身上相隔7天分两次采集样本。通过流式细胞术检测CD4和CD8 T淋巴细胞上CD25、人类淋巴细胞抗原（HLA-）DR、CD45RA和CD45RO的表达，并使用酶联免疫吸附测定技术测量血清白细胞介素-5（IL-5）浓度。在第1天，与对照组相比，哮喘患者中表达CD25、HLA-DR和CD45RO标志物的CD4 T淋巴细胞百分比显著更高，而表达CD45RA的CD4 T细胞百分比显著更低。糖皮质激素治疗后，哮喘患者中表达CD25、HLA-DR和CD45RO的CD4 T细胞百分比显著降低，而表达CD45RA的细胞百分比显著增加，以至于到第7天，所有四种标志物的表达与对照组不再有显著差异。相比之下，哮喘患者第1天PBMC中表达HLA-DR、CD45RA和CD45RO的CD8 T细胞百分比与对照组无显著差异，而表达CD25的CD8 T细胞百分比仅略有升高。糖皮质激素治疗导致CD8 T细胞上所有四种标志物的表达无显著变化。（摘要截断于250字）
